<DOC>
	<DOCNO>NCT02499237</DOCNO>
	<brief_summary>In contrast bisphosphonates , discontinuation denosumab result gradual loss bone mineral density gain . The investigator aim evaluate whether patient treat denosumab , single zoledronic acid infusion would prevent anticipated bone loss .</brief_summary>
	<brief_title>Zoledronic Acid Maintain Bone Mass After Denosumab Discontinuation</brief_title>
	<detailed_description>Discontinuation denosumab result rebound rise bone turnover marker gradual loss achieve bone mineral density gain . In contrast , bisphosphonates , zoledronic acid , remain within skeleton act several month even year discontinuation maintain bone mineral density despite cessation treatment . In study , investigator aim evaluate change bone mineral density lumbar spine femoral neck , well bone turnover marker one year treatment discontinuation denosumab-treated woman denosumab-treated woman switch zoledronic acid infusion one year treatment discontinuation .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>postmenopausal woman osteopenic ( Tscore &gt; 2.5 &lt; 1.0 ) treatment denosumab secondary osteoporosis ; disease could affect bone metabolism ; medication could affect bone metabolism ; history antiosteoporotic treatment denosumab prior randomization severe liver kidney disease ( creatinine clearance &lt; 60ml/min/1.73m2 )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>denosumab</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>bone marker</keyword>
</DOC>